Shake Shack $140 million common stock offering
Davis Polk advised the representative of the several underwriters in connection with the public offering of $140 million of Class A common stock of Shake Shack Inc. Shake Shack is listed on…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Shake Shack $75 million at-the-market offering
Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by Shake Shack Inc. of shares of its Class A common stock for up to a maximum offering…
BioXcel Therapeutics $73.6 million stock offering
Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 2,300,000 shares of its common stock. The common stock is listed on the…
Applied Genetic Technologies stock offering
Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 6,500,000 shares of common stock of Applied Genetic Technologies…
Beam Therapeutics $180 million IPO
Davis Polk advised the joint book-running managers in connection with the $180 million initial public offering of common stock of Beam Therapeutics Inc. The common stock is listed on the…
Integra LifeSciences Holdings $575 million convertible senior notes offering
Davis Polk advised the joint book-running managers and representatives of the initial purchasers on a Rule 144A offering by Integra LifeSciences Holdings Corporation of $575 million…
Progyny $149.5 Million Initial Public Offering and Nasdaq Listing
Davis Polk advised the underwriters on the SEC-registered initial public offering by Progyny, Inc. of 11,500,000 common shares, consisting of 6,700,000 shares sold by Progyny and 4,800,000…
Innate Pharma $79 Million U.S. Initial Public Offering of ADS on Nasdaq and Concurrent Private Placement
Davis Polk advised the underwriters in connection with an initial public offering of 8,047,227 American Depositary Shares of Innate Pharma S.A. and a concurrent private placement of 4,452…
BioNTech SE Initial Public Offering on Nasdaq
Davis Polk advised the underwriters in connection with the $150 million initial public offering of 10,000,000 American Depositary Shares of BioNTech SE. In addition, the underwriters have…
Beazer Homes USA, Inc. $350 Million Notes Offering and Concurrent Cash Tender Offer and Consent Solicitation
Davis Polk advised the joint book-running managers in connection with an offering by Beazer Homes USA, Inc. of $350 million aggregate principal amount of its 7.250% notes due 2029.
Davis…